文献速递心脑血管急症重症综合管理与镇静镇痛

直接口服抗凝药逆转剂用于颅内出血的系统评价与荟萃分析

Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2022-11-01
一句话结论缺乏随机对照比较试验时,4F-PCC、andexanet alfa与idarucizumab在DOAC相关颅内出血中的抗凝逆转率、全因死亡率和血栓栓塞事件率总体相似。

该系统评价与荟萃分析纳入36项研究、1832例成人DOAC相关颅内出血患者,其中967例接受4F-PCC、525例接受andexanet alfa、340例接受idarucizumab。4F-PCC抗凝逆转率77%(95%CI 72%-82%)、全因死亡率26%(95%CI 20%-32%)、血栓栓塞事件8%(95%CI 5%-12%);andexanet alfa分别为75%(95%CI 67%-81%)、24%(95%CI 16%-34%)、14%(95%CI 10%-19%);idarucizumab逆转达比加群分别为82%(95%CI 55%-95%)、11%(95%CI 8%-15%)、5%(95%CI 3%-8%)。4F-PCC与andexanet alfa的直接回顾性比较显示抗凝逆转、比例死亡率和血栓栓塞事件均无差异。在无随机临床比较试验的情况下,现有DOAC逆转剂在颅内出血管理中的总体结局似乎相似,费用、机构处方集状态和可及性可能限制逆转剂选择,尤其是在小型社区医院。

要点

  • DOAC相关颅内出血中,4F-PCC抗凝逆转率77%(95%CI 72%-82%)、全因死亡率26%(95%CI 20%-32%)、血栓栓塞事件8%(95%CI 5%-12%)。
  • andexanet alfa抗凝逆转率75%(95%CI 67%-81%)、全因死亡率24%(95%CI 16%-34%)、血栓栓塞事件14%(95%CI 10%-19%)。
  • idarucizumab用于逆转达比加群,抗凝逆转率82%(95%CI 55%-95%)、全因死亡率11%(95%CI 8%-15%)、血栓栓塞事件5%(95%CI 3%-8%)。
  • 4F-PCC与andexanet alfa的直接回顾性比较显示抗凝逆转、比例死亡率和血栓栓塞事件均无差异。
  • 在无随机临床比较试验的情况下,现有DOAC逆转剂的总体抗凝逆转、死亡和血栓栓塞事件率似乎相似;费用、机构处方集状态和可及性可能限制逆转剂选择。

适用人群与场景

  • 成人(年龄≥18岁)颅内出血且正在接受DOAC治疗的患者。
  • 研究排除:非人类研究、病例报告、需抗凝逆转的缺血性卒中患者、评估DOAC逆转剂不同剂量方案的研究、DOAC与华法林混合研究组。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,检索PubMed、MEDLINE、Cochrane Library、Embase、EBSCO、Web of Science和CINAHL数据库自建库至2022年4月29日,采用随机效应模型合并数据。
  • 共纳入36项研究、1832例患者:967例接受4因子凝血酶原复合物浓缩物(4F-PCC),525例接受andexanet alfa(AA),340例接受idarucizumab;平均年龄76岁(范围68-83岁),57%为男性。
  • 4F-PCC:抗凝逆转率77%(95%CI 72%-82%;I²=55%);全因死亡率26%(95%CI 20%-32%;I²=68%);血栓栓塞事件8%(95%CI 5%-12%;I²=41%)。
  • andexanet alfa:抗凝逆转率75%(95%CI 67%-81%;I²=48%);全因死亡率24%(95%CI 16%-34%;I²=73%);血栓栓塞事件14%(95%CI 10%-19%;I²=16%)。
  • idarucizumab逆转达比加群:抗凝逆转率82%(95%CI 55%-95%;I²=41%);全因死亡率11%(95%CI 8%-15%;I²=0%);血栓栓塞事件5%(95%CI 3%-8%;I²=0%)。
  • 4F-PCC与andexanet alfa的直接回顾性比较显示抗凝逆转、比例死亡率和血栓栓塞事件均无差异。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,遵循PRISMA指南进行数据提取和质量评估,由两名评价者独立选择研究并提取数据,采用随机效应模型合并数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在缺乏随机临床比较试验的情况下,本系统评价与荟萃分析显示现有DOAC逆转剂在颅内出血管理中的总体抗凝逆转、死亡和血栓栓塞事件率似乎相似。
  • 费用、机构处方集状态和可及性可能限制逆转剂选择,尤其是在小型社区医院。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Direct oral anticoagulant (DOAC)-associated intracranial hemorrhage (ICH) has high morbidity and mortality. The safety and outcome data of DOAC reversal agents in ICH are limited.

OBJECTIVE: To evaluate the safety and outcomes of DOAC reversal agents among patients with ICH.

DATA SOURCES: PubMed, MEDLINE, The Cochrane Library, Embase, EBSCO, Web of Science, and CINAHL databases were searched from inception through April 29, 2022.

STUDY SELECTION: The eligibility criteria were (1) adult patients (age ≥18 years) with ICH receiving treatment with a DOAC, (2) reversal of DOAC, and (3) reported safety and anticoagulation reversal outcomes. All nonhuman studies and case reports, studies evaluating patients with ischemic stroke requiring anticoagulation reversal or different dosing regimens of DOAC reversal agents, and mixed study groups with DOAC and warfarin were excluded.

DATA EXTRACTION AND SYNTHESIS: Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used for abstracting data and assessing data quality and validity. Two reviewers independently selected the studies and abstracted data. Data were pooled using the random-effects model.

MAIN OUTCOMES AND MEASURES: The primary outcome was proportion with anticoagulation reversed. The primary safety end points were all-cause mortality and thromboembolic events after the reversal agent.

RESULTS: A total of 36 studies met criteria for inclusion, with a total of 1832 patients (967 receiving 4-factor prothrombin complex concentrate [4F-PCC]; 525, andexanet alfa [AA]; 340, idarucizumab). The mean age was 76 (range, 68-83) years, and 57% were men. For 4F-PCC, anticoagulation reversal was 77% (95% CI, 72%-82%; I2 = 55%); all-cause mortality, 26% (95% CI, 20%-32%; I2 = 68%), and thromboembolic events, 8% (95% CI, 5%-12%; I2 = 41%). For AA, anticoagulation reversal was 75% (95% CI, 67%-81%; I2 = 48%); all-cause mortality, 24% (95% CI, 16%-34%; I2 = 73%), and thromboembolic events, 14% (95% CI, 10%-19%; I2 = 16%). Idarucizumab for reversal of dabigatran had an anticoagulation reversal rate of 82% (95% CI, 55%-95%; I2 = 41%), all-cause mortality, 11% (95% CI, 8%-15%, I2 = 0%), and thromboembolic events, 5% (95% CI, 3%-8%; I2 = 0%). A direct retrospective comparison of 4F-PCC and AA showed no differences in anticoagulation reversal, proportional mortality, or thromboembolic events.

CONCLUSIONS AND RELEVANCE: In the absence of randomized clinical comparison trials, the overall anticoagulation reversal, mortality, and thromboembolic event rates in this systematic review and meta-analysis appeared similar among available DOAC reversal agents for managing ICH. Cost, institutional formulary status, and availability may restrict reversal agent choice, particularly in small community hospitals.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Chaudhary R, Singh A, Chaudhary R, et al. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022. PMID: 36331504. doi:10.1001/jamanetworkopen.2022.40145

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。